134 related articles for article (PubMed ID: 8669892)
1. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127.
Zhang H; Vrang L; Bäckbro K; Lind P; Sahlberg C; Unge T; Oberg B
Antiviral Res; 1995 Dec; 28(4):331-42. PubMed ID: 8669892
[TBL] [Abstract][Full Text] [Related]
2. N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
Uckun FM; Mao C; Pendergrass S; Maher D; Zhu D; Tuel-Ahlgren L; Venkatachalam TK
Bioorg Med Chem Lett; 1999 Sep; 9(18):2721-6. PubMed ID: 10509923
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
Antivir Chem Chemother; 1999 Sep; 10(5):233-40. PubMed ID: 10574178
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138-->Arg and Tyr-188-->His mutations.
Zhang H; Vrang L; Bäckbro K; Unge T; Noréen R; Oberg B
Antiviral Res; 1994 May; 24(1):43-57. PubMed ID: 7524439
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
6. N-[2-(4-methylphenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea as a potent inhibitor of NNRTI-resistant and multidrug-resistant human immunodeficiency virus type 1.
Uckun FM; Mao C; Pendergrass S; Maher D; Zhu D; Tuel-Ahlgren L; Venkatachalam TK
Antivir Chem Chemother; 2000 Mar; 11(2):135-40. PubMed ID: 10819437
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
[TBL] [Abstract][Full Text] [Related]
8. Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.
Shao X; Rytting AS; Ekstrand DH; Vrang L; Källander CF; Gronowitz JS
Antivir Chem Chemother; 1998 Mar; 9(2):167-76. PubMed ID: 9875388
[TBL] [Abstract][Full Text] [Related]
9. Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors.
Taylor PB; Culp JS; Debouck C; Johnson RK; Patil AD; Woolf DJ; Brooks I; Hertzberg RP
J Biol Chem; 1994 Mar; 269(9):6325-31. PubMed ID: 7509800
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
Balzarini J; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; Bathurst IC; Barr PJ; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11831-8. PubMed ID: 1376314
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Debyser Z; Vandamme AM; Pauwels R; Baba M; Desmyter J; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11769-76. PubMed ID: 1376311
[TBL] [Abstract][Full Text] [Related]
12. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
Cantrell AS; Engelhardt P; Högberg M; Jaskunas SR; Johansson NG; Jordan CL; Kangasmetsä J; Kinnick MD; Lind P; Morin JM; Muesing MA; Noreén R; Oberg B; Pranc P; Sahlberg C; Ternansky RJ; Vasileff RT; Vrang L; West SJ; Zhang H
J Med Chem; 1996 Oct; 39(21):4261-74. PubMed ID: 8863804
[TBL] [Abstract][Full Text] [Related]
13. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs.
Bacolla A; Shih CK; Rose JM; Piras G; Warren TC; Grygon CA; Ingraham RH; Cousins RC; Greenwood DJ; Richman D
J Biol Chem; 1993 Aug; 268(22):16571-7. PubMed ID: 7688367
[TBL] [Abstract][Full Text] [Related]
14. Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
Venkatachalam TK; Sudbeck EA; Mao C; Uckun FM
Bioorg Med Chem Lett; 2000 Sep; 10(18):2071-4. PubMed ID: 10999473
[TBL] [Abstract][Full Text] [Related]
15. Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses.
Ren J; Diprose J; Warren J; Esnouf RM; Bird LE; Ikemizu S; Slater M; Milton J; Balzarini J; Stuart DI; Stammers DK
J Biol Chem; 2000 Feb; 275(8):5633-9. PubMed ID: 10681546
[TBL] [Abstract][Full Text] [Related]
16. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK
FEBS Lett; 1995 Aug; 370(1-2):59-62. PubMed ID: 7544302
[TBL] [Abstract][Full Text] [Related]
19. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
Tantillo C; Ding J; Jacobo-Molina A; Nanni RG; Boyer PL; Hughes SH; Pauwels R; Andries K; Janssen PA; Arnold E
J Mol Biol; 1994 Oct; 243(3):369-87. PubMed ID: 7525966
[TBL] [Abstract][Full Text] [Related]
20. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
